PROFIT JUMP: Drugmaker Merck's third-quarter profit of $1.69 billion was five times that of last year's quarter, which was depressed by $2.3 billion in after-tax charges.
REVENUE TREND: Favorable currency exchange rates brought more than half the 8 percent rise in total revenue, to $12.02 billion. That was down 1 percent from the second quarter.
DRUG SALES: Diabetes drugs and allergy medicine Singulair led growth, two vaccines had higher sales and a contraceptive and combo diabetes/cholesterol drug got approved. But new hepatitis C drug Victrelis got clobbered by rival Incivek.